Fig. 5: MiR-342 antagonizes EVL by targeting mRNAs, which are involved in lymphoid signaling pathways. | Leukemia

Fig. 5: MiR-342 antagonizes EVL by targeting mRNAs, which are involved in lymphoid signaling pathways.

From: The balance between the intronic miR-342 and its host gene Evl determines hematopoietic cell fate decision

Fig. 5

a Relative enrichment of the indicated miRNAs (miR-21, miR-142, miR-342) in mock and miR-342 (miR) overexpressing hematopoietic cells after AGO2 immunoprecipitation compared to IgG control samples. b Venn diagram of experimentally identified miR-342 target mRNAs (AGO2-IP enriched mRNAs) compared to in silico predicted targets and mRNAs expressed in LSK cells (Fig. 4c). c Relative luciferase activity (normalized to individual mutated UTR vector-transfected cells) in 293T cells after transfection with specific 3′UTR sequence containing constructs of predicted miR-342 target genes and the miR-342 overexpression vector. *P < 0.05; **P < 0.01; ***P < 0.001. d Western blot analysis of identified miR-342 target genes with lysates of murine bone marrow-derived 32D cells after inhibition of miR-342 using increasing amounts (MOI 1, 5, 25) of a specific miR-342 sponge vector (LV.miR-342-sponge) or its corresponding GFP-expressing control vector (LV.GFP-control). e Functional classification of the mRNAs, which are 1.5-fold enriched in miR-342 overexpressing samples compared to mock cells after AGO2-IP ranked by the number (no.) of genes in % of total genes within the given category.

Back to article page